These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1361349)

  • 21. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial.
    Boyer JD; Chattergoon MA; Ugen KE; Shah A; Bennett M; Cohen A; Nyland S; Lacy KE; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
    Clin Immunol; 1999 Jan; 90(1):100-7. PubMed ID: 9884357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.
    Lind A; Sommerfelt M; Holmberg JO; Baksaas I; Sørensen B; Kvale D
    Scand J Infect Dis; 2012 Aug; 44(8):566-72. PubMed ID: 22339485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.
    Churdboonchart V; Moss RB; Sirawaraporn W; Smutharaks B; Sutthent R; Jensen FC; Vacharak P; Grimes J; Theofan G; Carlo DJ
    AIDS; 1998 Aug; 12(12):1521-7. PubMed ID: 9727574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).
    Nyhus J; Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
    Vaccine; 2006 Mar; 24(10):1543-50. PubMed ID: 16289707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".
    MacGregor RR; Boyer JD; Ugen KE; Tebas P; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; Weiner DB
    Vaccine; 2005 Mar; 23(17-18):2066-73. PubMed ID: 15755572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral delivery of plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses.
    Lindh I; Bråve A; Hallengärd D; Hadad R; Kalbina I; Strid Å; Andersson S
    Vaccine; 2014 Apr; 32(20):2288-93. PubMed ID: 24631072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects.
    Cameron PU; Hunter SD; Jolley D; Sonza S; Mijch A; Crowe SM
    Cytometry; 1998 Sep; 33(1):83-8. PubMed ID: 9725562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24.
    Suzue K; Young RA
    J Immunol; 1996 Jan; 156(2):873-9. PubMed ID: 8543845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines.
    Steers NJ; Peachman KK; McClain S; Alving CR; Rao M
    Vaccine; 2009 Nov; 27(49):6939-49. PubMed ID: 19748578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
    Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The clinical and immunological correlations between the p24 antigenemia levels and those of anti-p24 antibodies in HIV-seropositive children].
    Apetrei C; Buzdugan I; Mitroi I; Duca M
    Bacteriol Virusol Parazitol Epidemiol; 1995; 40(2):141-4. PubMed ID: 7549257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
    Kran AM; Sommerfelt MA; Sørensen B; Nyhus J; Baksaas I; Bruun JN; Kvale D
    Vaccine; 2005 Jul; 23(31):4011-5. PubMed ID: 15963359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feeding of mice with Arabidopsis thaliana expressing the HIV-1 subtype C p24 antigen gives rise to systemic immune responses.
    Lindh I; Kalbina I; Thulin S; Scherbak N; Sävenstrand H; Bråve A; Hinkula J; Strid A; Andersson S
    APMIS; 2008 Nov; 116(11):985-94. PubMed ID: 19132995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides.
    Kran AM; Jonassen TO; Sommerfelt MA; Løvgården G; Sørensen B; Kvale D
    AIDS; 2010 Nov; 24(17):2609-18. PubMed ID: 20935558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
    Leroux-Roels I; Koutsoukos M; Clement F; Steyaert S; Janssens M; Bourguignon P; Cohen K; Altfeld M; Vandepapelière P; Pedneault L; McNally L; Leroux-Roels G; Voss G
    Vaccine; 2010 Oct; 28(43):7016-24. PubMed ID: 20728522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
    AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.